Navigation Links
Manhattan Research Ranks the Top Pharmaceutical Branded Websites by Rx Request Rates
Date:2/4/2008

While Chantix and Cialis Lead, Many Heavily Advertised Brands Lag Behind

NEW YORK, Feb. 4 /PRNewswire/ -- Manhattan Research, a leader in syndicated research and marketing services for the health and pharmaceutical industry, today revealed the top pharmaceutical branded product websites ranked by offline requests by U.S. adult consumers. The product site rankings are based on the comprehensive online consumer research study with 5,112 U.S. adults titled ePharma Consumer(R) v7.0: The Future of Integrated DTC Marketing. In addition to the top product site rankings, the study provides in-depth data on more than 200 leading pharmaceutical product sites including site satisfaction, site search rationales, tools and features desired on product sites, and a wide range of consumer actions taken afterwards.

"Having the most unique visitors is no longer the ultimate goal of a successful pharmaceutical product site," says Mark Bard, president of Manhattan Research. He continues, "Brand teams and agencies are being challenged to demonstrate the economic and strategic value created by these online destinations - beyond the raw number of visitors or page views. After all, if a site is all traffic and no action then what is the strategic value of the site?"

Top 10 Pharmaceutical Branded Websites Driving Prescription Drug Requests

1. Chantix

2. Cialis

3. Viagra

4. Aciphex

5. Ambien CR

6. Levitra

7. Lamisil

8. Lunesta

9. Wellbutrin XL

10. Ortho Evra

Source: ePharma Consumer(R) v7.0, Manhattan Research, LLC

To learn more about consumer segments of pharmaceutical information seekers, contact Manhattan Research by visiting http://www.manhattanresearch.com/ePC.htm or by emailing sales@manhattanresearch.com.

Some of the additional product sites researched within ePharma Consumer(R) v7.0 include the following: Abilify, Actonel, Advair, Aranesp, Aricept, Avandia, Boniva, Botox, Caduet, Concerta, Crestor, Cymbalta, Depakote, Depo- Provera, Detrol LA, Effexor XR, Enbrel, Flomax, Flonase, Flovent, Fosamax, Gardasil, Glucophage XR, Humira, Humulin, Imitrex, Lantus, Lexapro, Lipitor, Nasacort, Nasonex, Neulasta, Neurontin, Nexium, Norvasc, NuvaRing, Ortho Tri- Cyclen Lo, Paxil, Plavix, Pravachol, Prevacid, Protonix, Provigil, Pulmicort, Restasis, Risperdal, Rozerem, Seasonale, Seroquel, Singulair, Strattera, Tamiflu, Topamax, Toprol XL, Tricor, Valtrex, Vytorin, Yasmin, Yaz, Zocor, Zoloft, Zomig, Zyprexa and Zyrtec.

Please visit http://www.manhattanresearch.com/ePC.htm to download the ePharma Consumer(R) product brochure, request subscription information, and to listen to two audio presentations summarizing highlights from the research.

Manhattan Research

ePharma Consumer(R) v7.0 is a syndicated multi-client study and advisory service focused on key research topics and trends impacting online U.S. consumers seeking pharmaceutical information. The study was fielded in December 2007 among 5,112 U.S. adult consumers. In addition to ePharma Consumer(R), Manhattan Research conducts five additional research studies annually among consumers and physicians in the United States and in Europe: Cybercitizen(R) Health US, Cybercitizen(R) Health Europe, Taking the Pulse(R) US, Taking the Pulse(R) Europe, and ePharma Physician(R). Each study serves a unique purpose and focuses on specific aspects of information technology adoption. Broad consumer and physician research is complemented by targeted analyses among more than 50 consumer therapeutic segments and 25 physician specialist segments.

Contact:

Erica Alexander Martini

212-255-7799

Ealexander@Manhattanresearch.Com


'/>"/>
SOURCE Manhattan Research
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
4. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
5. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
6. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
7. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
8. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
9. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
10. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
11. Richard Schulz Receives the Coveted GCPj Award for Best Clinical Researcher of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... ... 20, 2016 , ... The recent recall by Costco and Trader Joes of ... on May 12, 2016(1), demonstrates the need for faster and more cost effective bio-threat ... PathSensors, Inc. , PathSensor’s latest solution uses a biosensor technology called ...
(Date:5/19/2016)... 19, 2016  AdvancedFlow Systems Inc. (AFS), a ... out of Maple Ridge, British Columbia ... its existing portfolio of contract manufacturing clients by ... with its sister companies Surround Technologies (STI) and ... industrial group that specializes in providing contract manufacturing ...
(Date:5/19/2016)... ... May 19, 2016 , ... KCAS Bioanalytical and Biomarker Services, ... Director, Large Molecule & Biomarker Bioanalysis. , Dr. Siddiqui has more than 15 ... for preclinical and clinical safety programs. “We’ve seen significant demand for, and we ...
(Date:5/19/2016)... -- - I dati saranno presentati nel ... ° Congresso della Società Americana ... - Le conclusioni dello studio indicano un tasso di risposta ... il 90% presenta una d urata della risposta (Duration ... per cento dei pazienti ha riscontrato un beneficio clinico. ...
Breaking Biology Technology:
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
Breaking Biology News(10 mins):